Overview PT003 MDI Dose Confirmation Study Status: Completed Trial end date: 2011-11-01 Target enrollment: Participant gender: Summary The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Phase: Phase 2 Details Lead Sponsor: Pearl Therapeutics, Inc.